四氢氨基吖啶对用单光子发射计算机断层扫描成像测量的阿尔茨海默病中锝-99m标记的双半胱乙酯潴留具有调节作用。

Tetrahydroaminoacridine modulates technetium-99m labelled ethylene dicysteinate retention in Alzheimer's disease measured with single photon emission computed tomography imaging.

作者信息

Riekkinen P, Kuikka J, Soininen H, Helkala E L, Hallikainen M, Riekkinen P

机构信息

Department of Neurology, University of Kuopio, Finland.

出版信息

Neurosci Lett. 1995 Jul 28;195(1):53-6. doi: 10.1016/0304-3940(95)11780-z.

DOI:10.1016/0304-3940(95)11780-z

PMID:7478254

Abstract

The present study investigated if acute treatment with tetrahydroaminoacridine (THA) (25 or 75 mg, p.o.) affects technetium-99m labelled ethylene dicysteinate (ECD) retention abnormalities in patients with mild to moderate Alzheimer's disease (AD; mean age 69 years). THA (75 mg) increased temporal, prefrontal and occipital ECD retention (normalized to cerebellum) in mildly demented AD patients, but 25 mg of THA had no effect on ECD retention. After 75 mg THA, prefrontal and temporal ECD retention correlated with improved executive and memory functioning, respectively. THA (25 or 75 mg) had no measurable effect on ECD retention of moderately demented patients.

摘要

本研究调查了用四氢氨基吖啶（THA）（25或75毫克，口服）进行急性治疗是否会影响轻度至中度阿尔茨海默病（AD；平均年龄69岁）患者中锝-99m标记的乙二胺半胱氨酸（ECD）潴留异常情况。THA（75毫克）增加了轻度痴呆AD患者颞叶、前额叶和枕叶的ECD潴留（以小脑为参照进行标准化），但25毫克的THA对ECD潴留没有影响。给予75毫克THA后，前额叶和颞叶的ECD潴留分别与执行功能和记忆功能的改善相关。THA（25或75毫克）对中度痴呆患者的ECD潴留没有可测量的影响。